Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy

Table 4

Standard incidence ratios (SIRs) for cancer in HIV-infected persons.

	30 years	30–59 years	60 years	Total
AIDS-defining cancer
Kaposi’s sarcoma
Male	280.37 (127.94, 372.43)	43.86 (36.42, 46.79)	23.55 (6.34, 37.39)	45.25 (37.94, 48.10)
Female	∞	82.37 (9.25, 165.59)	0	122.23 (32.89, 194.04)
Both	342.68 (170.83, 440.87)	44.20 (36.76, 47.12)	22.44 (6.04, 35.62)	46.09 (38.74, 48.94)
Non-Hodgkin’s lymphoma
Male	29.21 (9.41, 43.75)	5.14 (4.32, 5.45)	1.11 (0.55, 1.42)	4.17 (3.54, 4.42)
Female	0 (0, 0.65)	5.38 (3.41, 6.33)	2.11 (0.42, 3.66)	4.53 (2.96, 5.28)
Both	23.84 (7.68, 35.71)	5.17 (4.41, 5.46)	1.23 (0.67, 1.53)	4.22 (3.63, 4.45)
Non-AIDS-defining cancer
Colon/rectum
Male	0 (0, 0.42)	0.82 (0.60, 0.92)	0.50 (0.25, 0.65)	0.73 (0.55, 0.81)
Female	0 (0, 1.30)	0.52 (0.17, 0.78)	0.28 (0, 0.79)	0.45 (0.17, 0.65)
Both	0 (0, 0.32)	0.78 (0.58, 0.86)	0.47 (0.24, 0.60)	0.69 (0.53, 0.76)
Anus
Male	∞	34.93 (28.65, 37.42)	27.83 (14.81, 34.97)	34.28 (28.46, 36.56)
Female	∞	15.64 (8.08, 19.87)	15.79 (1.77, 31.74)	15.66 (8.55, 19.49)
Both	∞	31.09 (25.78, 33.18)	25.26 (14.13, 31.16)	30.54 (25.62, 32.46)
Lung, bronchus
Male	0 (0, 1.17)	0.85 (0.60, 0.96)	0.42 (0.23, 0.52)	0.66 (0.49, 0.74)
Female	0 (0, 4.72)	1.23 (0.59, 1.60)	0.41 (0.05, 0.83)	0.92 (0.48, 1.17)
Both	0 (0, 0.94)	0.91 (0.67, 1.01)	0.42 (0.24, 0.51)	0.70 (0.54, 0.77)
Prostate	∞	0.44 (0.33, 0.48)	0.74 (0.56, 0.82)	0.54 (0.45, 0.58)
Hodgkin’s lymphoma
Male	18.69 (5.03, 29.67)	10.81 (7.91, 12.07)	6.14 (1.23, 10.64)	10.69 (8.01, 11.84)
Female	0 (0, 0.34)	5.68 (1.53, 9.01)	0 (0, 0.39)	4.76 (1.28, 7.56)
Both	13.99 (3.76, 22.22)	10.08 (7.48, 11.20)	5.44 (1.09, 9.42)	9.83 (7.45, 10.84)